Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
- 27 January 2007
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 106 (2) , 181-189
- https://doi.org/10.1007/s10549-006-9492-5
Abstract
TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the impact of TOP2A amplification on the outcome of a series of patients homogeneously treated with adjuvant anthracyclines.Keywords
This publication has 46 references indexed in Scilit:
- Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancerEuropean Journal Of Cancer, 2006
- Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapyBritish Journal of Cancer, 2006
- Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancerBreast Cancer Research and Treatment, 2006
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancerBreast Cancer Research and Treatment, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapyEuropean Journal Of Cancer, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998